Literature DB >> 15635661

Site-specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia.

Brenda C Murphy1, Richard L O'Reilly, Shiva M Singh.   

Abstract

The catechol-o-methyltransferase (COMT) gene on chromosome 22q11 has been considered a strong candidate gene for schizophrenia (SZ) susceptibility. A functional Val/Met polymorphism in exon 4, with potential to affect COMT activity has been implicated in SZ, but the results remain inconclusive. We hypothesized that the association of COMT gene with SZ is not strictly a genetic alteration but could involve DNA methylation, as an epigenetic alteration. Thus, we chose to examine the cytosine DNA methylation profile of the human COMT promoter regions, which partially overlaps with the MB-COMT coding region and covers a total of 56 cytosines. Our analysis of 31 brain regions and 51 individual blood samples suggests that the cytosine methylation in his region is restricted to the CpG dinucleotides only. Also, the methylation pattern is nearly identical in the brain and blood with few exceptions. One cytosine (#27) is partially methylated in 5 brain regions and another cytosine (#23) is partially methylated in 81 of 82 samples studied. The exception being the blood DNA from a single SZ patient with prominent extreme negative symptoms, which was completely methylated. Interestingly, there was no difference in methylation at these sites in the blood DNA from three pairs of monozygotic twins discordant for SZ. The results support the use of blood DNA in methylation studies and rule out S-COMT promoter methylation as a common cause of SZ. The unique observation of a completely methylated cytosine 23 in one patient with SZ may have the potential to affect COMT mRNA transcription and gene activity, but remains to be evaluated. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15635661     DOI: 10.1002/ajmg.b.30134

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  34 in total

1.  Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.

Authors:  Doron Gothelf; Amanda J Law; Amos Frisch; Jingshan Chen; Omer Zarchi; Elena Michaelovsky; Renee Ren-Patterson; Barbara K Lipska; Miri Carmel; Bhaskar Kolachana; Abraham Weizman; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

2.  Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.

Authors:  Hamid Mostafavi Abdolmaleky; Kuang-Hung Cheng; Stephen V Faraone; Marsha Wilcox; Stephen J Glatt; Fangming Gao; Cassandra L Smith; Rahim Shafa; Batol Aeali; Julie Carnevale; Hongjie Pan; Panagiotis Papageorgis; Jose F Ponte; Vadivelu Sivaraman; Ming T Tsuang; Sam Thiagalingam
Journal:  Hum Mol Genet       Date:  2006-09-19       Impact factor: 6.150

3.  Epigenetic programming of the rRNA promoter by MBD3.

Authors:  Shelley E Brown; Moshe Szyf
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

4.  Epigenetics in mood disorders.

Authors:  Patrick O McGowan; Tadafumi Kato
Journal:  Environ Health Prev Med       Date:  2007-12-11       Impact factor: 3.674

5.  Catechol-O-Methyltransferase and UDP-Glucuronosyltransferases in the Metabolism of Baicalein in Different Species.

Authors:  Ruiya Zhang; Yonglei Cui; Yan Wang; Xiangge Tian; Lu Zheng; HaiJian Cong; Bin Wu; Xiaokui Huo; Chao Wang; BaoJing Zhang; Xiaobo Wang; Zhonghui Yu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

6.  The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia.

Authors:  S A Lott; P R Burghardt; K J Burghardt; M J Bly; T B Grove; V L Ellingrod
Journal:  Pharmacogenomics J       Date:  2012-03-06       Impact factor: 3.550

7.  DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia.

Authors:  Kazuya Iwamoto; Miki Bundo; Kazuo Yamada; Hitomi Takao; Yoshimi Iwayama-Shigeno; Takeo Yoshikawa; Tadafumi Kato
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

8.  DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences.

Authors:  Kyle J Burghardt; J Richard Pilsner; Michael J Bly; Vicki L Ellingrod
Journal:  Epigenomics       Date:  2012-06       Impact factor: 4.778

Review 9.  Epigenetic regulation in human brain-focus on histone lysine methylation.

Authors:  Schahram Akbarian; Hsien-Sung Huang
Journal:  Biol Psychiatry       Date:  2008-09-24       Impact factor: 13.382

10.  Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response.

Authors:  Katharina Domschke; Nicola Tidow; Kathrin Schwarte; Christiane Ziegler; Klaus-Peter Lesch; Jürgen Deckert; Volker Arolt; Peter Zwanzger; Bernhard T Baune
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.